These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35058411)

  • 1. Are High- or Low-dose SGLT2 Inhibitors Associated With Cardiovascular and Respiratory Adverse Events? A Meta-analysis.
    Zou HT; Yang GH; Cai YJ; Chen H; Zheng XQ; Hu R
    J Cardiovasc Pharmacol; 2022 May; 79(5):655-662. PubMed ID: 35058411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhan ZL; Liu SY
    Endocrine; 2021 Jul; 73(1):31-36. PubMed ID: 33559806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Xu B; Kang B; Zhou J
    Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials.
    Yin DG; Qiu M; Duan XY
    Front Pharmacol; 2021; 12():724405. PubMed ID: 34381370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
    Xu B; Kang B; Li S; Fan S; Zhou J
    J Endocrinol Invest; 2024 Oct; 47(10):2421-2436. PubMed ID: 38530620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis.
    Zhang HD; Ding L; Mi LJ; Zhang AK; Zhang K; Jiang ZH; Yu FY; Yan XX; Shen YJ; Tang M
    Eur J Prev Cardiol; 2024 May; 31(7):770-779. PubMed ID: 37966828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
    Wang A; Yang K; Wang T; Zhang N; Tang H; Feng X
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3174. PubMed ID: 31050384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Fatima K; Suri A; Rija A; Kalim S; Javaid S; Arif Z; Abedin MFE; Raza Y; Kalim N; Azam F; Musani S
    Curr Probl Cardiol; 2023 Apr; 48(4):101582. PubMed ID: 36584726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis.
    Liao XX; Li WQ; Peng ZK; Yu HB; Tan J
    J Clin Pharm Ther; 2022 May; 47(5):636-642. PubMed ID: 34939679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
    Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B
    Diabetes Res Clin Pract; 2018 Jun; 140():118-128. PubMed ID: 29604389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM
    Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.